1-2 of 2
Françoise Mechinaud, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease in High and Very High Risk ALL (HR/VHR-ALL) at the End of Induction (EOI) in FRALLE 2000 B and T Protocols.

Jean-Michel Cayuela, PhD, Kheira Beldjord, PhD, Nathalie Grardel, PhD, Hélène Cavé, PhD, Marie-Françoise Auclerc, MD, Anne Auvrignon, MD, Thierry Leblanc, MD, Yves Perel, MD, Françoise Mechinaud, MD, Claudine Schmitt, MD, Virginie Gandemer, MD, Pascale Schneider, MD, Claire Berger, MD, Xavier Rialland, MD, Catherine Paillard, MD, Odile Lejars, MD, Gerard Michel, MD, Guy Leverger, MD, Elizabeth A. Macintyre, MD, PhD, Andre Baruchel, MD
Journal: Blood
Blood (2007) 110 (11): 1427.
https://doi.org/10.1182/blood.V110.11.1427.1427
Published: 2007
Journal Articles

Two Decades of Progresses in Adolescents with Acute Lymphoblastic Leukemia (ALL) Treated in the FRALLE Protocols: Adolescence Is No More a Bad Prognostic Feature If an Intensive Chemotherapy Is Applied.

Andre Baruchel, MD, Marie-Françoise Auclerc, MD, Yves Perel, MD, Françoise Mechinaud, MD, Anne Auvrignon, MD, Claudine Schmitt, MD, Christophe Piguet, MD, Odile Lejars, MD, Christian Berthou, MD, François Demeocq, MD, Pascale Schneider, MD, Virginie Gandemer, MD, Gérard Michel, MD, Jean-Michel Cayuela, Pharm D, Thierry Leblanc, MD, Guy Leverger, MD, the FRALLE Group
Journal: Blood
Blood (2006) 108 (11): 1852.
https://doi.org/10.1182/blood.V108.11.1852.1852
Published: 2006